At any point during the CerenseSM assessment, the BBB delivery technology may be licensed for development of a pharmaceutical product on an exclusive worldwide basis.
CerenseSM is available exclusively through a partnership between Genzyme Pharmaceuticals and Pharmidex Pharmaceutical Services. The product development platform can be confidentially reviewed at your company and a customised programme of study tailored to your specific drug therapy needs. Drug compounds are assessed under a Product Collaboration Agreement that is exclusive for the duration of your study.
Read cerense literature here
